Announced
Synopsis
RA Capital, a multi-stage investment manager, agreed to invest $200m in Novavax, a late-stage biotechnology company, at an effective purchase price per share of common stock equal to the June 12, 2020 closing price. "The global vaccine effort is searching for candidates that are capable of both generating the highest neutralizing antibody titers and large-scale production. We are excited to increase our investment in Novavax, which along with resources from CEPI and the US Department of Defense, will support Novavax in its important work developing an effective, scalable vaccine for SARS-CoV-2," Peter Kolchinsky, RA Capital Managing Partner.
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.